Sorafenib versus sunitinib as first-line treatment agents in Chinese patients with metastatic renal cell carcinoma: the largest multicenter retrospective analysis of survival and prognostic factors

被引：0
|
作者：
Hai-Liang Zhang
Xi-Nan Sheng
Xue-Song Li
Hong-Kai Wang
Zhi-Hong Chi
Zhi-Song He
Ding-Wei Ye
Jun Guo
机构：
[1] Department of Urology,Department of Oncology
[2] Fudan University Shanghai Cancer Center,Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma
[3] Shanghai Medical College,Department of Urology, Peking University First Hospital, Institute of Urology, National Urological Cancer Center
[4] Fudan University,undefined
[5] Peking University Cancer Hospital & Institute,undefined
[6] Peking University,undefined
来源：
BMC Cancer | / 17卷
关键词：
Metastatic renal cell carcinoma; Sorafenib; Sunitinib; Prognosis; Survival;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Sorafenib versus sunitinib as first-line treatment agents in Chinese patients with metastatic renal cell carcinoma: the largest multicenter retrospective analysis of survival and prognostic factors
    Zhang, Hai-Liang
    Sheng, Xi-Nan
    Li, Xue-Song
    Wang, Hong-Kai
    Chi, Zhi-Hong
    He, Zhi-Song
    Ye, Ding-Wei
    Guo, Jun
    BMC CANCER, 2017, 17
  • [2] Sorafenib versus sunitinib as first-line treatment in metastatic renal cell carcinoma: Largest multicenter retrospective analysis.
    Sheng, Xinan
    Zhang, Hailiang
    Li, Xuesong
    Chi, Zhihong
    He, Zhisong
    Ye, Dingwei
    Guo, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [3] Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis
    Sheng, Xinan
    Chi, Zhihong
    Cui, Chuanliang
    Si, Lu
    Li, Siming
    Tang, Bixia
    Mao, Lili
    Lian, Bin
    Wang, Xuan
    Yan, Xieqiao
    Guo, Jun
    ONCOTARGET, 2016, 7 (19) : 27044 - 27054
  • [4] COMPARATIVE EFFICACY OF SUNITINIB VERSUS SORAFENIB AS THE FIRST-LINE TREATMENT FOR PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
    Park, S. J.
    Lee, J.
    Park, I.
    Park, K.
    Ahn, J.
    Lee, D. H.
    Song, C.
    Hong, J. H.
    Kim, C.
    Ahn, H.
    ANNALS OF ONCOLOGY, 2012, 23 : 287 - 288
  • [5] Comparative Efficacy of Sunitinib versus Sorafenib as First-Line Treatment for Patients with Metastatic Renal Cell Carcinoma
    Park, Seong Joon
    Lee, Jae-Lyun
    Park, Inkeun
    Park, Kwonoh
    Ahn, Yongcheol
    Ahn, Jin-Hee
    Lee, Dae-Ho
    Ahn, Shin
    Song, Cheryn
    Hong, Jun Hyuk
    Kim, Choung-Soo
    Ahn, Hanjong
    CHEMOTHERAPY, 2012, 58 (06) : 468 - 474
  • [6] Comparative efficacy of sunitinib versus sorafenib as the first-line treatment for patients with metastatic renal cell carcinoma.
    Park, Seongjoon
    Lee, Jae-Lyun
    Park, Inkeun
    Park, Kwonoh
    Ahn, Yongchel
    Ahn, Jin-Hee
    Lee, Dae Ho
    Song, Cheryn
    Hong, Jun Hyuk
    Kim, Choung-Soo
    Ahn, Hanjong
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [7] Axitinib versus sunitinib as first-line therapies for metastatic renal cell carcinoma: A multicenter retrospective analysis.
    Hatakeyama, Shingo
    Tanaka, Toshiaki
    Ikehata, Yoshinori
    Fujita, Naoki
    Masumori, Naoya
    Kitamura, Hiroshi
    Yoneyama, Takahiro
    Hashimoto, Yasuhiro
    Ohyama, Chikara
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [8] Prognostic factors for overall survival with sunitinib as first-line therapy in patients with metastatic renal cell carcinoma (mRCC)
    Patil, S.
    Figlin, R. A.
    Hutson, T. E.
    Michaelson, M. D.
    Negrier, S.
    Kim, S. T.
    Huang, X.
    Motzer, R. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [9] Economic Evaluation of Everolimus versus Sorafenib for the Treatment of Metastatic Renal Cell Carcinoma after Failure of First-Line Sunitinib
    Casciano, Roman
    Chulikavit, Maruit
    Di Lorenzo, Giuseppe
    Liu, Zhimei
    Baladi, Jean-Francois
    Wang, Xufang
    Robertson, Justin
    Garrison, Lou
    VALUE IN HEALTH, 2011, 14 (06) : 846 - 851
  • [10] Efficacy and safety of first-line sunitinib in Chinese patients with metastatic renal cell carcinoma
    Qin, Shu-Kui
    Jin, Jie
    Guo, Jun
    Wang, Jin-Wan
    Zhou, Fang-Dian
    Huang, Yi-Ran
    Ren, Xiu-Bao
    Ye, Ding-Wei
    Pan, Sharon
    Sajben, Peter
    Wang, Qiao
    FUTURE ONCOLOGY, 2018, 14 (18) : 1835 - 1845
12345